Nuvation Bio Inc (NUVB)
2.39
-0.03 (-1.24%)
USD |
NYSE |
Jan 30, 13:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 521.96M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -57.24% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.7815 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
01/06 08:31
MT Newswires
12/20 12:37
Yahoo
12/07 05:03
Yahoo
11/03 16:05
MT Newswires
08/22 08:36
Yahoo
08/11 10:01
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/28/2023* | -- | Results | Q4 2022 | -- | -0.11 | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.11 | -0.15 | 24.25% | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.14 | -0.11 | -26.18% | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.08 | -0.13 | 36.15% | |
| 02/28/2022 | -- | Results | Q4 2021 | -- | -0.11 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. |
| URL | https://www.nuvationbio.com |
| Investor Relations URL | https://investors.nuvationbio.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 125.01M |
| Net Income (TTM) | -108.49M |
| Total Assets (Quarterly) | 686.49M |
| Total Liabilities (Quarterly) | 18.55M |
| Shareholders Equity (Quarterly) | 667.94M |
| Cash from Operations (TTM) | -103.42M |
| Cash from Investing (TTM) | -103.98M |
| Cash from Financing (TTM) | 1.458M |
Ratings
Profile
Edit
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. |
| URL | https://www.nuvationbio.com |
| Investor Relations URL | https://investors.nuvationbio.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| BBC | 160983.0 USD | 0.96% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NUVB Tweets |